MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

MDS Virtual Congress 2021

September 17-22, 2021. Virtual Congress. www.mdscongress.org

View by Title View Categories
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Peripheral neuromodulation for the treatment of bladder symptoms associated with Parkinson’s disease

    M. Smith, Y. Ben-Shlomo, E. Henderson (Bristol, United Kingdom)

  • Perivascular spaces in the basal ganglia and long-term motor prognosis in newly diagnosed Parkinson’s disease

    SJ. Chung, YJ. Kim, PH. Lee, YH. Sohn (Yongin-Si, Republic of Korea)

  • Persistent and efficient transduction of the putamen following gene therapy for aromatic L-amino acid decarboxylase deficiency

    Y. Onuki, S. Ono, T. Nakajima, K. Kojima, N. Taga, K. Kawai, T. Sato, S. Muramatsu, T. Yamagata (Yakushiji, Japan)

  • Personality dimensions could be predictive of quality-of-life outcome after deep brain stimulation of the sub-thalamic nucleus in Parkinson’s Disease

    M. Boussac, T. Danaila, A. Eusebio, E. Hainque, JC. Corvol, O. Rascol, C. Moreau, AS. Rolland, D. Devos, S. Ansquer, OL. Boukbiza, AR. Marques, D. Maltete, S. Drapier, B. Jarraya, L. Belamri, P. Burbaud, M. Meyer, T. Rouaud, B. Giordana, M. Tir, C. Brefel-Courbon (Toulouse, France)

  • Perspectives of People with Parkinson Disease Managing Exercise during the COVID-19 Pandemic: A Qualitative Study

    Q. Hanses, A. Yorke, J. Haines (Flint, USA)

  • Pharmacokinetic–pharmacodynamics of levodopa/carbidopa following subcutaneous infusion with ND0612: Results from the BeyoND pharmacokinetic substudy

    T. Birnberg, L. Adar, W. Poewe, M. Bjornsson, M. Karlsson (Rehovot, Israel)

  • Phase 1/2 Open-label Dose Evaluation Study of AXO-Lenti-PD Gene Therapy for Parkinson’s Disease: Efficacy, Safety, and Tolerability Data from the Second Cohort at 6 Months

    G. Corcoran, A. Karunakara, B. Vaughn, E. Brand-Schieber, T. Foltynie, R. Barker, S. Palfi (New York, USA)

  • Phenotype characteristics of ANO10 mutation carries: a case series from Serbia and a systematic review of the literature

    I. Stankovic, N. Dragasevic, A. Milovanovic, AA. Marjanovic, M. Brankovic, V. Dobricic, I. Petrovic, M. Svetel, I. Novakovic, V. Kostic (Belgrade, Serbia)

  • Phenotype-genotype correlation in a case series from South Spain of Hereditary Spastic Paraplegia 7 (SPG7)

    A. Adarmes Gómez, S. Jesús Maestre, D. Macias Garcia, L. Muñóz, F. Carrillo Garcia, M. Gómez Garré, P. Mir (Seville, Spain)

  • Physical activity (PA), patient reported outcomes and quality of life in Parkinson’s disease( PD)

    J. Morley, I. Subramanian, J. Farahnik, L. Mischley (Philadelphia, USA)

  • « Previous Page
  • 1
  • …
  • 89
  • 90
  • 91
  • 92
  • 93
  • …
  • 132
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley